Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1017998 | 0.87 | XDH (0.63) | XDHALDH1A1HPGD | |
| SCHEMBL30863521 | 0.85 | XDH (0.43) | XDHALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL4286296 | 0.84 | PDE4B (0.52) | PARP15PARP10PARP2 | |
| SCHEMBL1015940 | 0.84 | XDH (0.51) | XDHALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL1013024 | 0.81 | KMO (0.52) | HPGDPARP15PARP10PARP2 | |
| SCHEMBL17050364 | 0.80 | PDE4B (0.46) | PARP15PARP10PARP2 | |
| SCHEMBL15968595 | 0.80 | PDE4B (0.46) | PARP15PARP10PARP2 | |
| Hydrochloric Acid SCHEMBL28514645 | 0.80 | XDH (0.46) | XDH | |
| SCHEMBL1030016 | 0.79 | PDE4B (0.61) | — | |
| SCHEMBL30950126 | 0.78 | ALDH1A1 (0.43) | ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329730-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-12-11 | — | — | US | disclosed |
| US-8329730-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-12-11 | — | — | US | disclosed |
| EP-2271643-B1 | OXADIAZOLES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2012-08-15 | — | — | EP | disclosed |
| EP-2271643-B1 | OXADIAZOLES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2012-08-15 | — | — | EP | disclosed |
| US-20110039889-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-02-17 | — | — | US | disclosed |
| US-20110039889-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-02-17 | — | — | US | disclosed |
| EP-2271643-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009133136-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009133136-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039889-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | XDH 106/4885ALDH1A1 427/4885HPGD 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.